Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07448298) titled 'A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases' on Feb. 26.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Beijing Boren Hospital
Condition:
Relapsed/Refractory Autoimmune Diseases
Intervention:
Biological: AFN50 injection
Recruitment Status: Recruiting
Phase: Early Phase 1
Date of First Enrollment: March 9, 2026
Target Sample Size: 18
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07448298
Published by HT Digital...